The Pharma Data

SEPTEMBER 10, 2020

Pfizer-BioNTech announced Wednesday that preliminary preclinical data from mouse and macaque monkey models showed a strong immune response from its mRNA COVID-19 vaccine. . Photo by Md. Tareq Aziz Touhid.

Immune Response 52

Immune Response Vaccine Vaccination RNA 52

Pharmaceutical Technology

NOVEMBER 22, 2022

Devex’s global COVID-19 funding dashboard recorded $172 million invested in vaccine research between 1 January 2020 and 27 June 2020. Research into the therapeutic use of mRNA had been ongoing for decades prior to the COVID-19 pandemic. This August, the Biomedical Advanced Research and Development Authority awarded Arcturus $63.2

Manufacturing 130

Manufacturing Vaccine Vaccination RNA 130

pharmaphorum

AUGUST 31, 2021

Just a few months after breaking cover with its new take on RNA therapeutics, Laronde has raised an impressive $440 million in second-round financing backed by Flagship Pioneering – which was behind the founding of mRNA specialist Moderna. The post ‘Endless RNA’ startup Laronde raises $440m to fuel pipeline appeared first on.

RNA 52

RNA Protein Immune Response Medicine 52

pharmaphorum

JANUARY 5, 2022

A COVID-19 vaccine that could work against multiple variants of the coronavirus – developed by US biotech Gritstone bio – has generated encouraging immune response data in its first clinical trial.

Protein 126

Protein Vaccine Vaccination Immune Response 126

Roots Analysis

OCTOBER 30, 2023

In the past few years, Next Generation RNA therapeutics have emerged as one of the key therapeutic modalities in the modern healthcare industry. These RNA based therapeutics play a crucial role in protein production and regulation of gene functions.

RNA 40

RNA Vaccine Vaccination Development 40

Delveinsight

SEPTEMBER 23, 2021

858 Therapeutics closes USD 60 Million series A round to drug RNA modulation. Now, they are ready for their next venture, which is launching RNA biotech 858 Therapeutics with a USD 60 million Series A fundraising. 858’s drug candidates include proteins, which regulate RNA and immune response. Stafford and co.

RNA 61

RNA Gene Therapy Gene Protein 61

The Pharma Data

OCTOBER 25, 2020

German drugmaker CureVac said preclinical studies of its COVID-19 vaccine candidate, CVnCoV, showed the vaccination prompted a successful immune response. The messenger RNA-based vaccine, which is designed to block replication of the coronavirus, was shown to induce neutralizing antibodies and activate T-cells in hamsters and mice.

Vaccine 52

Vaccine Vaccination Immune Response RNA 52

Pharmaceutical Technology

FEBRUARY 15, 2023

The non-structural proteins NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5 are involved in viral RNA replication and dampening of the host innate immune response. To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.

Vaccine 130

Vaccine Vaccination Protein Immune Response 130

Delveinsight

AUGUST 26, 2021

Shape’s RNA editing technologies can modify the RNA sequence, which makes the body’s protein building blocks. This system is designed to deliver RNA editing technology or other payloads directly to particular body areas, such as the nervous system or muscle. and Leila Zegna, director of the Kabuki Syndrome Foundation.

Vaccine 98

Vaccine Vaccination Gene Therapy RNA 98

pharmaphorum

JANUARY 10, 2023

Since then, the two partners have developed multiple AI-based applications including a platform for selecting neoantigens for use in individualised cancer vaccines and an early warning system for high risk SARS-CoV-2 variants based on how well they can evade the immune system and their transmissibility.

Vaccination 116

Vaccination Vaccine Clinical Trials Clinical Trials 116

XTalks

NOVEMBER 30, 2023

Over the last 35 years, substantial strides have been made in tackling HIV/AIDS, propelled by advancements in medical research, enhanced accessibility to treatment and prevention and a more comprehensive understanding of the virus. World AIDS Day offers an occasion for reflection on the strides achieved thus far.

FDA Approval 111

FDA Approval Gene Therapy Gene Clinical Trials 111

Worldwide Clinical Trials

JUNE 15, 2022

We’ve also seen a decrease in available research nurses, as they have had to be reassigned to COVID patients. There have been a few cases lately where patients receiving gene therapy had a severe adverse effect because of their immune response to the mechanism of the AAV viral vector, based on their own genomic markers.

Gene Therapy 130

Gene Therapy Gene Clinical Trials Clinical Trials 130

pharmaphorum

OCTOBER 2, 2020

NEO, which is designed to be produced on-demand according to the neoantigen profile of an individual patient and produces an immune response that attacks the tumour. Frame Therapeutics has also begun work on neoantigen-based cancer vaccines based on RNA technology. The deal focuses on Vaccibody’s investigational product VB10.NEO,

Vaccine 59

Vaccine Vaccination Immune Response Drugs 59

The Pharma Data

MARCH 8, 2022

SARS-CoV-2 viruses can hide from recognition by the immune system. However, the antiviral immune receptor RIG-I can be stimulated, which improves protection against lethal SARS-CoV-2 infections. Researchers led by Prof. Camouflage protects virus from immune system. Samira Marx, Beate M.

Immune Response 52

Immune Response RNA Protein Genetics 52

pharmaphorum

SEPTEMBER 14, 2021

Repeat sequences aren’t involved in expressing proteins so have been generally under-studied by researchers, but there is increasing evidence that some human traits and diseases may be associated with mutations within them. That muffles the immune system response and allows the cancer to grow.

DNA 52

DNA Immune Response Genome Genomics 52

pharmaphorum

FEBRUARY 9, 2021

InteRNA is focusing on the development of gene-silencing drugs based on microRNA, naturally occurring, non-coding strands of RNA that are thought to regulate gene expression in cells. The major difference between siRNAs and microRNAs is that the former are very specific to one messenger RNA target, while the latter can have multiple targets.

Trials 59

Trials Gene Silencing RNA Gene Expression 59

The Pharma Data

DECEMBER 14, 2020

Supported by promising phase 1 data, CureVac announced Monday that it has enrolled the first participant in the pivotal phase 2b/3 study of its messenger-RNA based coronavirus vaccine, CVnCoV. The company announced positive phase 1 trial results in November that demonstrated its candidate elicited immune responses and was well-tolerated.

Vaccine 52

Vaccine Vaccination Trials Immune Response 52

pharmaphorum

OCTOBER 12, 2022

Genomic medicine is a rapidly growing space in which researchers use the information in a person’s genes to identify and administer medical treatment.”. Genomic medicine is a rapidly growing space in which researchers use the information in a person’s genes to identify and administer medical treatment. About Whitelab Genomics.

Genome 105

Genome Genomics Medicine Development 105

The Pharma Data

JULY 6, 2021

But HIV’s ability to mutate isn’t unique among RNA viruses – most viruses develop mutations, or changes in their genetic code, over time. Half of the recovered COVID-19 patients studied had T cell responses to highly networked epitopes identified by the research team.

Vaccine 52

Vaccine Vaccination Research Immune Response 52

The Pharma Data

DECEMBER 3, 2020

Strong Th1 cell-mediated immune responses were also observed for the vaccine candidates with either adjuvant. We are encouraged by the high level of neutralizing antibodies in combination with the strong Th1 response which we believe could play an important role in controlling infection.

Vaccine 52

Vaccine Vaccination Immune Response Protein 52

The Pharma Data

DECEMBER 8, 2020

Overall, the vaccine protected against symptomatic disease in 70% of cases, according to a team led by researchers from Oxford University in England. ” Previous clinical trials of the vaccine had found that the vaccine triggers antibody and T-cell immune responses, and is safe in people aged 18 and older. TUESDAY, Dec.

Vaccine 52

Vaccine Vaccination Trials Immune Response 52

The Pharma Data

MAY 17, 2021

Sanofi and GlaxoSmithKline (GSK) have reemerged as COVID-19 vaccine contenders after their reformulated candidate delivered a strong immune response across all age groups in a phase 2 study. 14, 2020 ). The mRNA candidate is currently being assessed in a phase 1/2 study.

Vaccine 40

Vaccine Vaccination Immune Response RNA 40

The Pharma Data

JULY 18, 2021

Clinical Data Supporting Approval Demonstrated Non-Inferior Immune Responses for the Serotypes Shared with PCV13 (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F). VAXNEUVANCE Elicited Superior Immune Responses for Serotypes 3, 22F and 33F Compared to PCV13, Which Are Major Causes of Disease.

Immune Response 52

Immune Response Vaccine Vaccination FDA Approval 52

XTalks

JUNE 5, 2023

Today’s approval is a monumental step forward in delivering on Pfizer’s commitment to help alleviate the significant burden of RSV in higher-risk populations, which includes older adults,” said Annaliesa Anderson, PhD, senior VP and chief scientific officer, Vaccine Research and Development at Pfizer, in the company’s news release.

Vaccine 98

Vaccine Vaccination FDA Approval Protein 98

The Pharma Data

SEPTEMBER 30, 2021

. “We used NanoSTING because the adjuvant for intranasal vaccination and single-cell RNA-sequencing to verify the nasal-associated lymphatic tissue as an inductive site upon vaccination. The nasal vaccine also will serve to equitably distribute vaccines worldwide, consistent with the researchers.

Vaccine 52

Vaccine Vaccination Immune Response Licensing 52

The Pharma Data

JUNE 26, 2021

Sanofi Pasteur, the vaccines global business unit of Sanofi and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, have initiated a Phase 1 clinical trial evaluating an mRNA-based investigational vaccine against seasonal influenza. JUNE 22 , 2021.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccine Vaccination 52

The Pharma Data

JANUARY 31, 2021

Adjuvanted S-Trimer COVID-19 vaccine candidates demonstrated favorable safety and tolerability profiles and strong neutralizing immune responses in a phase 1 trial. Dynavax is also advancing CpG 1018 as an advanced vaccine adjuvant through research collaborations and partnerships. CHENGDU, China , Feb.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccine Vaccination 52

Roots Analysis

AUGUST 23, 2024

The idea behind mRNA vaccines is to use this natural process to incite an immune response: inject patients with a synthetic mRNA strand encoding a particular antigen – usually a protein, or part of a protein, recognized by the immune system – and their cells will produce the antigen in situ.

Protein 40

Protein Vaccine Vaccination Immune Response 40

pharmaphorum

JANUARY 17, 2023

Research into mRNA dates back to the 1970s, but with the approval of both Moderna and BioNTech/Pfizer’s vaccines, this approach has finally been validated. Once its potential as a means of stimulating an immune response had been established, attention quickly turned to where else the technology could provide a therapeutic solution.

Vaccination 97

Vaccination Vaccine In-Vivo In-Vitro 97

The Pharma Data

MARCH 11, 2021

Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels. This collaboration brings together Sanofi Pasteur’s leadership in vaccines and Translate Bio’s mRNA research and development expertise.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccine Vaccination 52

pharmaphorum

NOVEMBER 4, 2022

The influenza virus is subject to constant mutations to evade host immune response, and this causes the seasonal variation in circulating strains. The follow-up period for each participant will be a total of six months. Both were based on BioNTech’s proprietary mRNA platform technology.

Vaccine 52

Vaccine Vaccination Immune Response RNA 52

The Pharma Data

JANUARY 21, 2021

market specifically target the spike protein to prevent transmission, explained Dr. Kathryn Edwards, scientific director of the Vanderbilt University Vaccine Research Program in Nashville. “The height of the antibody response may be somewhat proportional to how sick you are in the beginning. “The spike is really critical.

Vaccine 52

Vaccine Vaccination Protein Immune Response 52

Roots Analysis

MAY 21, 2024

Amidst the ongoing initiatives to develop therapeutic interventions with improved bioavailability, lipid nanoparticle (LNPs) have specifically attracted the attention of researchers and drug developers. LNPs are spherical vesicles made up of ionizable lipids that are neutral at physiological pH and positively charged at low pH.

Drug Delivery 40

Drug Delivery Drugs Gene Therapy Bioavailability 40

The Pharma Data

SEPTEMBER 9, 2020

Immunization of non-human primates (rhesus macaques) with BNT162b2, a nucleoside-modified messenger RNA (modRNA) candidate that expresses the SARS-CoV-2 spike glycoprotein, resulted in strong anti-viral effects against an infectious SARS-CoV-2 challenge. Senior Vice President and Head of Vaccine Research & Development, Pfizer. “We

Vaccine 52

Vaccine Vaccination RNA Clinical Trials 52

The Pharma Data

JANUARY 31, 2021

Clover’s S-Trimer antigen adjuvanted with CpG 1018 plus alum demonstrated low reactogenicity while providing high levels of neutralizing antibodies and a strong Th1-biased cell-mediated immune response. Dynavax developed CpG 1018 to provide an increased vaccine immune response, which has been demonstrated in HEPLISAV-B.

Vaccine 52

Vaccine Vaccination Trials Protein 52

The Pharma Data

OCTOBER 25, 2020

The Phase 1 interim analysis showed that mRNA-1273 was generally well-tolerated across all age groups and induced rapid and strong immune responses against SARS-CoV-2. Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. 26, 2020 11:00 UTC. CAMBRIDGE, Mass.–(

Vaccine 52

Vaccine Vaccination Manufacturing Clinical Development 52

pharmaphorum

SEPTEMBER 22, 2022

The beauty of that T-cell response is that you can actually access the internal parts of the virus,” Le Vert states. Osivax’s technology, oligoDOM, trains the T-cell immune response to recognise the nucleoprotein. It just takes a lot of work and a lot of good science, but we’re ready for that.”

Vaccine 97

Vaccine Vaccination Antibody Clinical Trials 97